NASDAQ:DRMA Dermata Therapeutics (DRMA) Stock Price, News & Analysis → 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad) Free DRMA Stock Alerts $3.52 -0.24 (-6.38%) (As of 12:27 PM ET) Add Compare Share Share Today's Range$3.52▼$5.0050-Day Range$3.76▼$6.5252-Week Range$3.48▼$38.55Volume199,055 shsAverage Volume42,817 shsMarket Capitalization$1.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Dermata Therapeutics alerts: Email Address Ad Stansberry Research41 banks launch ‘crypto dollar’Everyone knows the US financial system is in the middle of a radical change... The White House wants an all-digital dollar. Plus at least 41 major banks (see if your bank is one of them right here).Here's how you capitalize (including #1 crypto to play it). About Dermata Therapeutics Stock (NASDAQ:DRMA)Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Read More DRMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRMA Stock News HeadlinesMay 19 at 6:33 PM | uk.investing.comDermata Therapeutics announces warrant exercise and new issuanceMay 16, 2024 | investorplace.comDRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q1 2024February 11, 2024 | ca.finance.yahoo.comDermata Therapeutics, Inc. (DRMAW)February 6, 2024 | finance.yahoo.comPresenting on the Emerging Growth Conference 67 Day 1 on February 7 Register NowFebruary 4, 2024 | morningstar.comDermata Therapeutics Inc DRMAFebruary 1, 2024 | finance.yahoo.comDermata to Present at the Emerging Growth Conference on February 7, 2024January 7, 2024 | msn.comDermata stock soars on patent issuance, partnership talksJanuary 5, 2024 | msn.comDow Turns Lower; ISM Services PMI Falls In DecemberJanuary 5, 2024 | msn.comWhy Is Aesthetic Skin Conditions-Focused Dermata Therapeutics Stock Trading Higher Today?January 5, 2024 | investorplace.comWhy Is Dermata Therapeutics (DRMA) Stock Up 62% Today?January 4, 2024 | marketwatch.comStocks to Watch: Dermata Therapeutics, Applied Therapeutics, Fusion PharmaceuticalsJanuary 4, 2024 | marketwatch.comDermata Therapeutics Shares Surge 120% on Patent Issued in JapanJanuary 4, 2024 | msn.comWhy Dermata Therapeutics Stock Took Off After-HoursJanuary 4, 2024 | finance.yahoo.comDermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of HyperhidrosisDecember 21, 2023 | finanznachrichten.deDermata Therapeutics: Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDecember 20, 2023 | benzinga.comDermata Therapeutics Stock (NASDAQ:DRMA) Dividends: History, Yield and DatesDecember 20, 2023 | finance.yahoo.comDermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDecember 13, 2023 | thestreet.comDermata Therapeutics Inc.November 16, 2023 | finance.yahoo.comDermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq RulesNovember 16, 2023 | finance.yahoo.comDermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 ProtocolsNovember 10, 2023 | msn.comDermata Therapeutics GAAP EPS of -$0.54November 9, 2023 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsOctober 26, 2023 | finance.yahoo.comDermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne TrialAugust 31, 2023 | finance.yahoo.comDermata to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 11, 2023 | finance.yahoo.comDermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsSee More Headlines Receive DRMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/21/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DRMA CUSIPN/A CIK1853816 Webwww.dermatarx.com Phone858-800-2543FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($27.7362) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-141.27% Return on Assets-119.03% Debt Debt-to-Equity RatioN/A Current Ratio3.78 Quick Ratio3.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$24.24 per share Price / Book0.16Miscellaneous Outstanding Shares440,000Free Float425,000Market Cap$1.65 million OptionableNot Optionable Beta0.89 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Gerald T. Proehl (Age 65)Founder, President, CEO & Chairman Comp: $392kMr. David F. Hale (Age 75)Co-Founder & Lead Independent Director Comp: $73kMs. Kyri K. Van Hoose CPA (Age 46)M.B.A., Senior VP & CFO Comp: $415.8kDr. Christopher J. Nardo M.P.H. (Age 59)Ph.D., Senior VP & Chief Development Officer Comp: $443.52kMr. Sean ProehlSenior Director of Legal & Business DevelopmentDr. Maria Bedoya Toro Munera M.B.A. (Age 73)Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance Comp: $27.04kMore ExecutivesKey CompetitorsAvenue TherapeuticsNASDAQ:ATXIAltamira TherapeuticsNASDAQ:CYTOClearmind MedicineNASDAQ:CMNDCNS PharmaceuticalsNASDAQ:CNSPSalarius PharmaceuticalsNASDAQ:SLRXView All Competitors DRMA Stock Analysis - Frequently Asked Questions How have DRMA shares performed in 2024? Dermata Therapeutics' stock was trading at $9.15 at the start of the year. Since then, DRMA shares have decreased by 61.5% and is now trading at $3.52. View the best growth stocks for 2024 here. When is Dermata Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our DRMA earnings forecast. How were Dermata Therapeutics' earnings last quarter? Dermata Therapeutics, Inc. (NASDAQ:DRMA) posted its quarterly earnings data on Thursday, March, 21st. The company reported ($3.15) earnings per share (EPS) for the quarter. When did Dermata Therapeutics' stock split? Dermata Therapeutics's stock reverse split before market open on Thursday, May 16th 2024. The 1-15 reverse split was announced on Thursday, May 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Dermata Therapeutics IPO? Dermata Therapeutics (DRMA) raised $18 million in an initial public offering on Friday, August 13th 2021. The company issued 2,571,428 shares at a price of $7.00 per share. How do I buy shares of Dermata Therapeutics? Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DRMA) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsNext President (Not Trump. Not Biden.)The Freeport SocietyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlaceElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.